{"title":"抗骨质疏松治疗对血浆醛固酮和肾素的影响。","authors":"Qingfen Hu, Kangla Liao, Longwei Zhang, Xiaoyu Shu, Zhixin Xu, Yuyang Qiu, Qifu Li, Shumin Yang","doi":"10.1177/1470320320928874","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to investigate the effect of anti-osteoporosis therapy on plasma aldosterone concentration (PAC), plasma renin concentration (PRC) and the aldosterone/renin ratio (ARR) in patients with postmenopausal osteoporosis.</p><p><strong>Methods: </strong>In 60 patients with postmenopausal osteoporosis, bone mineral density (BMD), PAC and PRC were measured before and after treatment with alendronate (70 mg/week, <i>n</i>=22) or recombinant human parathyroid hormone (20 μg/day, <i>n</i>=35) for 48 weeks.</p><p><strong>Results: </strong>PAC was negatively correlated with the T-score of lumbar spine BMD and femoral neck BMD (lumbar <i>r</i>=-0.386, <i>p</i><0.01; femoral neck <i>r</i>=-0.262, <i>p</i><0.05). With the improvement in lumbar BMD after anti-osteoporosis treatment (T-score -3.4±0.5 vs. -3.1 ±0.4, <i>p</i><0.0001), PAC decreased from 182.8±53.2 to 143.7±68.6 pg/mL (<i>p</i><0.0001), PRC increased from 7.8±11.6 to 39.2±50.0 μIU/mL (<i>p</i><0.0001) and the ARR decreased from 74.8±75.2 to 13.1±17.1 pg/μIU (<i>p</i><0.0001). At baseline, 58% (35/60) of the patients had an ARR >37 pg/μIU, and the proportion decreased to 8% (5/57) after treatment.</p><p><strong>Conclusion: </strong>Treatment with alendronate or parathyroid hormone causes decreased PAC and increased PRC, resulting in a decreased ARR in postmenopausal women with osteoporosis.</p>","PeriodicalId":17330,"journal":{"name":"Journal of the Renin-Angiotensin-Aldosterone System","volume":"21 2","pages":"1470320320928874"},"PeriodicalIF":2.1000,"publicationDate":"2020-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1470320320928874","citationCount":"1","resultStr":"{\"title\":\"Effects of anti-osteoporosis therapy on plasma aldosterone and renin.\",\"authors\":\"Qingfen Hu, Kangla Liao, Longwei Zhang, Xiaoyu Shu, Zhixin Xu, Yuyang Qiu, Qifu Li, Shumin Yang\",\"doi\":\"10.1177/1470320320928874\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>This study aimed to investigate the effect of anti-osteoporosis therapy on plasma aldosterone concentration (PAC), plasma renin concentration (PRC) and the aldosterone/renin ratio (ARR) in patients with postmenopausal osteoporosis.</p><p><strong>Methods: </strong>In 60 patients with postmenopausal osteoporosis, bone mineral density (BMD), PAC and PRC were measured before and after treatment with alendronate (70 mg/week, <i>n</i>=22) or recombinant human parathyroid hormone (20 μg/day, <i>n</i>=35) for 48 weeks.</p><p><strong>Results: </strong>PAC was negatively correlated with the T-score of lumbar spine BMD and femoral neck BMD (lumbar <i>r</i>=-0.386, <i>p</i><0.01; femoral neck <i>r</i>=-0.262, <i>p</i><0.05). With the improvement in lumbar BMD after anti-osteoporosis treatment (T-score -3.4±0.5 vs. -3.1 ±0.4, <i>p</i><0.0001), PAC decreased from 182.8±53.2 to 143.7±68.6 pg/mL (<i>p</i><0.0001), PRC increased from 7.8±11.6 to 39.2±50.0 μIU/mL (<i>p</i><0.0001) and the ARR decreased from 74.8±75.2 to 13.1±17.1 pg/μIU (<i>p</i><0.0001). At baseline, 58% (35/60) of the patients had an ARR >37 pg/μIU, and the proportion decreased to 8% (5/57) after treatment.</p><p><strong>Conclusion: </strong>Treatment with alendronate or parathyroid hormone causes decreased PAC and increased PRC, resulting in a decreased ARR in postmenopausal women with osteoporosis.</p>\",\"PeriodicalId\":17330,\"journal\":{\"name\":\"Journal of the Renin-Angiotensin-Aldosterone System\",\"volume\":\"21 2\",\"pages\":\"1470320320928874\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2020-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1177/1470320320928874\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of the Renin-Angiotensin-Aldosterone System\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/1470320320928874\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"PERIPHERAL VASCULAR DISEASE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the Renin-Angiotensin-Aldosterone System","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/1470320320928874","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
Effects of anti-osteoporosis therapy on plasma aldosterone and renin.
Objective: This study aimed to investigate the effect of anti-osteoporosis therapy on plasma aldosterone concentration (PAC), plasma renin concentration (PRC) and the aldosterone/renin ratio (ARR) in patients with postmenopausal osteoporosis.
Methods: In 60 patients with postmenopausal osteoporosis, bone mineral density (BMD), PAC and PRC were measured before and after treatment with alendronate (70 mg/week, n=22) or recombinant human parathyroid hormone (20 μg/day, n=35) for 48 weeks.
Results: PAC was negatively correlated with the T-score of lumbar spine BMD and femoral neck BMD (lumbar r=-0.386, p<0.01; femoral neck r=-0.262, p<0.05). With the improvement in lumbar BMD after anti-osteoporosis treatment (T-score -3.4±0.5 vs. -3.1 ±0.4, p<0.0001), PAC decreased from 182.8±53.2 to 143.7±68.6 pg/mL (p<0.0001), PRC increased from 7.8±11.6 to 39.2±50.0 μIU/mL (p<0.0001) and the ARR decreased from 74.8±75.2 to 13.1±17.1 pg/μIU (p<0.0001). At baseline, 58% (35/60) of the patients had an ARR >37 pg/μIU, and the proportion decreased to 8% (5/57) after treatment.
Conclusion: Treatment with alendronate or parathyroid hormone causes decreased PAC and increased PRC, resulting in a decreased ARR in postmenopausal women with osteoporosis.
期刊介绍：
JRAAS is a peer-reviewed, open access journal, serving as a resource for biomedical professionals, primarily with an active interest in the renin-angiotensin-aldosterone system in humans and other mammals. It publishes original research and reviews on the normal and abnormal function of this system and its pharmacology and therapeutics, mostly in a cardiovascular context but including research in all areas where this system is present, including the brain, lungs and gastro-intestinal tract.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
